SPRI | Hormone Therapy And Castration Resistance Of Prostate Cancer (2018 EN)

Discussion in 'Medicine' started by Kanka, May 30, 2018.

  1. Kanka

    Kanka Well-Known Member Loyal User

    Messages:
    16,086
    Likes Received:
    446
    Trophy Points:
    83
    [​IMG]

    Author: Yoichi Arai (Editor), Osamu Ogawa (Editor)
    Full Title: Hormone Therapy And Castration Resistance Of Prostate Cancer
    Publisher: Springer; 1st ed. 2018 edition (May 11, 2018)
    Year: 2018
    ISBN-13: 9789811070136 (978-981-10-7013-6), 9789811070129 (978-981-10-7012-9)
    ISBN-10: 981107013X, 9811070121
    Pages: 433
    Language: English
    Genre: Medicine: Urology
    File type: EPUB (True), PDF (True)
    Quality: 10/10
    Price: 155.99 €


    This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged.

    During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.

    -------------
     
    Last edited by a moderator: Dec 6, 2019